Skip to main content
xMedica

NCT07439653ClinicalTrials.gov

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Phase 1 / Phase 2155 participants sought9 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 3 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 155 participants (target), run at 9 sites.

How this score is built
  • Enrolment21/40

    155 participants (target)

  • Site count6/25

    3 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale3/10

    TORL Biotherapeutics, LLC has led 10 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Conditions

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 1 / Phase 2
AllocationNon-randomised
Intervention modelSEQUENTIAL
Primary purposeTREATMENT
MaskingNONE (0)
Enrolment155 participants sought

Sponsor and collaborators

  • TORL Biotherapeutics, LLC Sponsor

Arms and interventions

  • Part 1: Monotherapy Dose EscalationEXPERIMENTAL

    TORL-5-700 Administered once every three weeks

  • Part 2: Monotherapy ExpansionEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks

  • Part 3: Combination EvaluationEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Interventions

  • Drug TORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • Drug TORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • Drug TORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Outcome measures

  1. Primary outcome

    Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Time frame though study completion, an average of 2.5 years

  2. Primary outcome

    Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    Time frame though study completion, an average of 2.5 years

  3. Primary outcome

    Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Time frame though study completion, an average of 2.5 years

  4. Primary outcome

    Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    Time frame 21 days from the start of treatment

  5. Primary outcome

    Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    Time frame 21 days from the start of treatment

  6. Secondary outcome

    Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  7. Secondary outcome

    Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  8. Secondary outcome

    Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  9. Secondary outcome

    Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  10. Secondary outcome

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  11. Secondary outcome

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  12. Secondary outcome

    Clearance (CL) of TORL-5-700

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  13. Secondary outcome

    Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    Time frame though end of study treatment, an average of 5 months

  14. Secondary outcome

    Volume of distribution of TORL-5-700

    PK assessment

    Time frame though end of study treatment, an average of 5 months

  15. Secondary outcome

    Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    Time frame though end of study treatment, an average of 5 months

  16. Secondary outcome

    Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Time frame though end of study treatment, an average of 5 months

  17. Secondary outcome

    Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Time frame though end of study treatment, an average of 5 months

  18. Secondary outcome

    Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    Time frame though study completion, an average of 2.5 years

Dates

Dates
Start dateMarch 31, 2026 (actual)
Primary completionMarch 31, 2029 (estimated)
CompletionSeptember 30, 2029 (estimated)
First postedFebruary 27, 2026 (actual)
Last updatedSeptember 28, 2026
Results postedNot stated in the registry record
Status last verifiedAugust 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

9 sites are recruiting

United States

United States
FacilityCityState or regionStatus
University of Texas Southwestern Medical CenterDallasTexasRecruiting
Providence Medical FoundationFullertonCaliforniaRecruiting
University of Iowa Health CareIowa CityIowaRecruiting
Cancer and Blood Specialty Clinic, Los AlamitosLos AlamitosCaliforniaRecruiting
University of California Miami, Sylvester Comprehensive Cancer CenterMiamiFloridaRecruiting
Sarah Cannon Research InstituteNashvilleTennesseeRecruiting
UCLASanta MonicaCaliforniaRecruiting
Stanford UniversityStanfordCaliforniaRecruiting
Cancer Center of Kansas, WichitaWichitaKansasRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. September 28, 2026

    Site added

    3 sites added (9 total)

    69

  2. August 24, 2026

    Site added

    3 sites added (6 total)

    36